Replies to post #87698 on Biotech Values

[genisi]

ANA598 rash

I'm a notch less skeptic than I was after the monotherapy data, as rash incidents in the ANA598+SOC treatment were all mild and the only moderate rash case was in the control arm. Of course, longer treatment and higher dose may induce more rash.